RU2756619C2 - Жидкая композиция антитела против TNF альфа - Google Patents

Жидкая композиция антитела против TNF альфа Download PDF

Info

Publication number
RU2756619C2
RU2756619C2 RU2019130728A RU2019130728A RU2756619C2 RU 2756619 C2 RU2756619 C2 RU 2756619C2 RU 2019130728 A RU2019130728 A RU 2019130728A RU 2019130728 A RU2019130728 A RU 2019130728A RU 2756619 C2 RU2756619 C2 RU 2756619C2
Authority
RU
Russia
Prior art keywords
composition
compositions
adalimumab
arginine
liquid composition
Prior art date
Application number
RU2019130728A
Other languages
English (en)
Russian (ru)
Other versions
RU2019130728A3 (fr
RU2019130728A (ru
Inventor
Сора ЮН
Ён Кён КО
Чжинон СО
Original Assignee
ЭлДжи КЕМ, ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2756619(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ЭлДжи КЕМ, ЛТД. filed Critical ЭлДжи КЕМ, ЛТД.
Publication of RU2019130728A3 publication Critical patent/RU2019130728A3/ru
Publication of RU2019130728A publication Critical patent/RU2019130728A/ru
Application granted granted Critical
Publication of RU2756619C2 publication Critical patent/RU2756619C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2019130728A 2017-03-16 2018-03-16 Жидкая композиция антитела против TNF альфа RU2756619C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0033188 2017-03-16
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (fr) 2017-03-16 2018-03-16 Formulation liquide d'anticorps anti-tnf alpha

Publications (3)

Publication Number Publication Date
RU2019130728A3 RU2019130728A3 (fr) 2021-04-16
RU2019130728A RU2019130728A (ru) 2021-04-16
RU2756619C2 true RU2756619C2 (ru) 2021-10-04

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019130728A RU2756619C2 (ru) 2017-03-16 2018-03-16 Жидкая композиция антитела против TNF альфа

Country Status (15)

Country Link
JP (2) JP7109849B2 (fr)
KR (2) KR20180106974A (fr)
CN (1) CN110621303A (fr)
AU (1) AU2018236651B2 (fr)
BR (1) BR112019019162A2 (fr)
CO (1) CO2019010860A2 (fr)
MA (1) MA46988A1 (fr)
MX (1) MX2019010895A (fr)
MY (1) MY197202A (fr)
NZ (1) NZ757965A (fr)
PH (1) PH12019502075A1 (fr)
RU (1) RU2756619C2 (fr)
UA (1) UA123847C2 (fr)
WO (1) WO2018169348A1 (fr)
ZA (1) ZA201906696B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012065072A2 (fr) * 2010-11-11 2012-05-18 Abbott Biotechnology Ltd. Formulation liquide d'anticorps anti-tnfα hautement concentrée améliorée
WO2015151115A1 (fr) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Composition pharmaceutique liquide d'adalimumab
WO2015177057A1 (fr) * 2014-05-23 2015-11-26 Ares Trading S.A. Composition pharmaceutique liquide
WO2016066688A1 (fr) * 2014-10-28 2016-05-06 Richter Gedeon Nyrt. Formulation pharmaceutique d'anticorps anti-tnf-alpha
WO2016120413A1 (fr) * 2015-01-28 2016-08-04 Mabxience S.A. Formulations pharmaceutiques pour des anticorps anti-tnf-alpha
WO2016162819A1 (fr) * 2015-04-07 2016-10-13 Lupin Limited Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha
US20160304599A1 (en) * 2012-09-07 2016-10-20 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
SG10201609982PA (en) * 2012-03-07 2017-01-27 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha anitbodies
EP2948473A1 (fr) * 2013-01-24 2015-12-02 GlaxoSmithKline Intellectual Property Development Limited Protéines de liaison à l'antigène tnf-alpha
AR095496A1 (es) * 2013-03-15 2015-10-21 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US20150274819A1 (en) * 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012065072A2 (fr) * 2010-11-11 2012-05-18 Abbott Biotechnology Ltd. Formulation liquide d'anticorps anti-tnfα hautement concentrée améliorée
US20160304599A1 (en) * 2012-09-07 2016-10-20 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
WO2015151115A1 (fr) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Composition pharmaceutique liquide d'adalimumab
WO2015177057A1 (fr) * 2014-05-23 2015-11-26 Ares Trading S.A. Composition pharmaceutique liquide
WO2016066688A1 (fr) * 2014-10-28 2016-05-06 Richter Gedeon Nyrt. Formulation pharmaceutique d'anticorps anti-tnf-alpha
WO2016120413A1 (fr) * 2015-01-28 2016-08-04 Mabxience S.A. Formulations pharmaceutiques pour des anticorps anti-tnf-alpha
WO2016162819A1 (fr) * 2015-04-07 2016-10-13 Lupin Limited Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha

Also Published As

Publication number Publication date
JP2020510079A (ja) 2020-04-02
MY197202A (en) 2023-05-31
JP2022097600A (ja) 2022-06-30
RU2019130728A3 (fr) 2021-04-16
KR20200096472A (ko) 2020-08-12
JP7109849B2 (ja) 2022-08-01
WO2018169348A1 (fr) 2018-09-20
CO2019010860A2 (es) 2020-01-17
AU2018236651A1 (en) 2019-10-31
UA123847C2 (uk) 2021-06-09
KR20180106974A (ko) 2018-10-01
PH12019502075A1 (en) 2020-09-14
MA46988A1 (fr) 2020-06-30
AU2018236651B2 (en) 2020-12-10
NZ757965A (en) 2022-07-01
MX2019010895A (es) 2019-11-05
KR102342292B1 (ko) 2021-12-24
ZA201906696B (en) 2020-08-26
BR112019019162A2 (pt) 2020-04-14
RU2019130728A (ru) 2021-04-16
CN110621303A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
US20190345238A1 (en) Formulations
JP6798882B2 (ja) ＴＮＦＲ及びＦｃ領域を含む融合タンパク質の液体製剤
WO2016128564A1 (fr) Formulation liquide stable pour des anticorps monoclonaux
EP3143047B1 (fr) Formulation de belimumab
RU2756619C2 (ru) Жидкая композиция антитела против TNF альфа
EP3730126A1 (fr) Composition liquide comprenant un antagoniste du vegf
CN110536698B (zh) 重组单克隆抗TNFα抗体的水性药用组合物
AU2020207124A1 (en) Pharmaceutical composition comprising antibody, device comprising same, and use thereof
AU2014201388B2 (en) Stable Buffered Formulations Containing Polypeptides
AU2016213875A1 (en) Stable Buffered Formulations Containing Polypeptides
EP3533441A2 (fr) Formulation pharmaceutique stable